Yoga Therapy Attenuates the Progression of Diabetes - Insights from Proteomics and Metabolomics Analysis

Overview

Journal Int J Yoga

Date 2025 Feb 17

PMID 39959515

Authors

Babasaheb P Sonwane

Pooja Raut

Jyotsna Chitalkar

Smita Godbole

Shanta Sabnis

Jyoti Gupta

B Santhakumari

Mukund V Deshpande

Mahesh J Kulkarni

Affiliations

Soon will be listed here.

Abstract

Objective: Diabetes management remains challenging despite advancements in therapeutics, with many subjects developing complications. Yoga has been shown to aid diabetes management. This study investigates the impact of yoga therapy on diabetes progression, utilizing proteomics and metabolomics analyses to explore underlying molecular mechanisms.

Methodology: A 3-month longitudinal study involving healthy subjects with prediabetes and diabetes was conducted. Blood glucose, glycated hemoglobin (HbA1c), lipid profile, and malondialdehyde (MDA) levels were measured before and after the yoga intervention.

Results And Conclusion: Healthy subjects showed no significant changes in blood glucose, lipid profile, HbA1c, or MDA levels. However, subjects with prediabetes and diabetes experienced positive changes, with decreases in HbA1c and MDA levels. Proteomics and metabolomics analyses provided insights into the molecular mechanisms by which yoga attenuates diabetes progression in subjects with prediabetes and diabetes. This study is a pioneering effort to understand the molecular basis of yoga's beneficial effects on diabetes management.

References

Innes K, Selfe T . Yoga for Adults with Type 2 Diabetes: A Systematic Review of Controlled Trials. J Diabetes Res. 2016; 2016:6979370. PMC: 4691612. DOI: 10.1155/2016/6979370. View

Dhali B, Chatterjee S, Sundar Das S, Cruz M . Effect of Yoga and Walking on Glycemic Control for the Management of Type 2 Diabetes: A Systematic Review and Meta-analysis. J ASEAN Fed Endocr Soc. 2023; 38(2):113-122. PMC: 10692414. DOI: 10.15605/jafes.038.02.20. View

Dambrova M, Makrecka-Kuka M, Kuka J, Vilskersts R, Nordberg D, Attwood M . Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. Pharmacol Rev. 2022; 74(3):506-551. DOI: 10.1124/pharmrev.121.000408. View

Gualano B, DE Salles Painneli V, Roschel H, Artioli G, Neves Jr M, de Sa Pinto A . Creatine in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Med Sci Sports Exerc. 2010; 43(5):770-8. DOI: 10.1249/MSS.0b013e3181fcee7d. View

Korwar A, Vannuruswamy G, G Jagadeeshaprasad M, Jayaramaiah R, Bhat S, Regin B . Development of Diagnostic Fragment Ion Library for Glycated Peptides of Human Serum Albumin: Targeted Quantification in Prediabetic, Diabetic, and Microalbuminuria Plasma by Parallel Reaction Monitoring, SWATH, and MSE. Mol Cell Proteomics. 2015; 14(8):2150-9. PMC: 4528244. DOI: 10.1074/mcp.M115.050518. View

Lee C, Lee T, Galvan E, Chen V, Bui S, Crouse S . The Effect of Choline and Resistance Training on Strength and Lean Mass in Older Adults. Nutrients. 2023; 15(18). PMC: 10534351. DOI: 10.3390/nu15183874. View

Li X, Zong J, Si S . Complement Factor H related protein 1 and immune inflammatory disorders. Mol Immunol. 2022; 145:43-49. DOI: 10.1016/j.molimm.2022.03.117. View

Solis M, Artioli G, Gualano B . Potential of Creatine in Glucose Management and Diabetes. Nutrients. 2021; 13(2). PMC: 7915263. DOI: 10.3390/nu13020570. View

Datey P, Hankey A, Nagendra H . Combined Ayurveda and Yoga Practices for Newly Diagnosed Type 2 Diabetes Mellitus: A Controlled Trial. Complement Med Res. 2017; 25(1):16-23. DOI: 10.1159/000464441. View

10.

Xie B, Nguyen P, Idevall-Hagren O . Feedback regulation of insulin secretion by extended synaptotagmin-1. FASEB J. 2018; 33(4):4716-4728. DOI: 10.1096/fj.201801878R. View

11.

Hsiao C, Cheng H, Huang C, Li H, Ou M, Huang J . Fibronectin in cell adhesion and migration via N-glycosylation. Oncotarget. 2017; 8(41):70653-70668. PMC: 5642584. DOI: 10.18632/oncotarget.19969. View

12.

. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2023; 47(Suppl 1):S20-S42. PMC: 10725812. DOI: 10.2337/dc24-S002. View

13.

Shantakumari N, Sequeira S, El deeb R . Effects of a yoga intervention on lipid profiles of diabetes patients with dyslipidemia. Indian Heart J. 2013; 65(2):127-31. PMC: 3861018. DOI: 10.1016/j.ihj.2013.02.010. View

14.

Van Campenhout A, van Campenhout C, Lagrou A, Manuel-y-Keenoy B . Transferrin modifications and lipid peroxidation: implications in diabetes mellitus. Free Radic Res. 2004; 37(10):1069-77. DOI: 10.1080/10715760310001600390. View

15.

Gao H, Wu J, Sun Z, Zhang F, Shi T, Lu K . Influence of lecithin cholesterol acyltransferase alteration during different pathophysiologic conditions: A 45 years bibliometrics analysis. Front Pharmacol. 2023; 13:1062249. PMC: 9795195. DOI: 10.3389/fphar.2022.1062249. View

16.

Stefan N, Hennige A, Staiger H, Machann J, Schick F, Krober S . Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 2006; 29(4):853-7. DOI: 10.2337/diacare.29.04.06.dc05-1938. View

17.

Manohar S, Vaikasuvu S, Deepthi K, Sachan A, Narasimha S . An association of hyperglycemia with plasma malondialdehyde and atherogenic lipid risk factors in newly diagnosed Type 2 diabetic patients. J Res Med Sci. 2013; 18(2):89-93. PMC: 3724384. View

18.

Tsugawa H, cajka T, Kind T, Ma Y, Higgins B, Ikeda K . MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. Nat Methods. 2015; 12(6):523-6. PMC: 4449330. DOI: 10.1038/nmeth.3393. View

19.

Lee Y, Kim J, Park K, Lee M . β-cell autophagy: Mechanism and role in β-cell dysfunction. Mol Metab. 2019; 27S:S92-S103. PMC: 6768496. DOI: 10.1016/j.molmet.2019.06.014. View

20.

Gawel S, Wardas M, Niedworok E, Wardas P . [Malondialdehyde (MDA) as a lipid peroxidation marker]. Wiad Lek. 2005; 57(9-10):453-5. View